Dr. Arbour on the Latest Data for Checkpoint Inhibitors for Lung Cancer in 2019

Satri-cel led to a median PFS of 3.25 months vs 1.77 months with physician’s choice in patients with pretreated gastric or gastroesophageal cancer.

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

A phase 2 trial demonstrated a median overall survival of 43.5 months at 60 Gy compared with 22.5 months at 45 Gy in patients with limited-stage SCLC.

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

THIO with cemiplimab is active and well-tolerated in patients with advanced non–small cell lung cancer resistant to immune checkpoint inhibitors in second- and third-line settings.

Data from DeLLphi-304 support tarlatamab as a preferable second-line therapy for patients with small cell lung cancer.